Tech Company Financing Transactions
Calidi Biotherapeutics Funding Round
On 1/24/2020, Calidi Biotherapeutics announced Series A investment from Greentable and Won & Partners.
Transaction Overview
Company Name
Announced On
1/24/2020
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance manufacturing in preparation for its pre-IND and IND filings.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10210 Campus Point Dr. 150
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the utilization of oncolytic viruses through an allogeneic cell-based delivery system. Calidi Biotherapeutics is advancing this potent stem cell and oncolytic virus (SN-V1c-vaccinia virus) combination for use in multiple difficult-to-treat oncology indications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Allan Camaisa
Chief Medical Officer
Boris Minev
Vice President
Dobrin Draganov
VP - Bus. Development
Stephen Keane
VP - Operations
Stephen Thesing
VP - R & D
Antonio Santidrian
Browse more venture capital transactions:
Prev: 1/24/2020: Communo venture capital transaction
Next: 1/24/2020: Proxyclick venture capital transaction
Share this article
Where The Data Comes From
We document funding rounds that are announced publicly. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs